Mobile

A 16-week treatment, multicenter, randomized, double blind, placebo-controlled, parallel-group study to assess the effect of omalizumab on the expression of FcεRI receptors of blood basophils and dend...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-010937-38

A 16-week treatment, multicenter, randomized, double blind, placebo-controlled, parallel-group study to assess the effect of omalizumab on the expression of FcεRI receptors of blood basophils and dendritic cells in patients with severe persistent non-atopic asthma, uncontrolled despite optimal therapy

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

• To study the change from baseline in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo.

Critère d'inclusion

  • severe persistent non-atopic asthma

Liens